Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors.
Am J Trop Med Hyg
; 68(2): 147-52, 2003 Feb.
Article
em En
| MEDLINE
| ID: mdl-12641403
ABSTRACT
Artemisinin derivatives are first-line antimalarial drugs in Thailand. No firm evidence of clinically relevant artemisinin resistance exists. When used as monotherapy, artesunate has been associated with a high treatment failure (recrudescence) rate, which could be due to low-level artemisinin resistance. To understand the causes of recrudescence, we retrospectively studied a cohort of 104 malaria patients treated with artesunate monotherapy, 32 of whom recrudesced. There was no difference in in vitro artesunate sensitivities between 6 nonrecrudescent isolates and 16 paired admission and recrudescent isolates. Paired admission and recrudescent isolates from 10 patients were genotyped; only 3 had pfmdr1 mutations. Patients with admission parasitemias >10,000 per microl had a 9-fold higher likelihood of recrudescence (adjusted odds ratio) compared with patients with lower parasitemias. This study suggests (1) recrudescence after treatment with artesunate is not the result of inherent parasite resistance, and (2) admission parasitemia may be useful in choosing therapeutic options.
Buscar no Google
Base de dados:
MEDLINE
Métodos Terapêuticos e Terapias MTCI:
Terapias_biologicas
/
Aromoterapia
Assunto principal:
Plasmodium falciparum
/
Sesquiterpenos
/
Proteínas de Protozoários
/
Malária Falciparum
/
Transportadores de Cassetes de Ligação de ATP
/
Artemisininas
/
Antimaláricos
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
País/Região como assunto:
Asia
Idioma:
En
Revista:
Am J Trop Med Hyg
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Tailândia